Fenbendazole and Cancer: The Story, the Science, and the Issues Patients Need to Hear

The question comes up almost as often as ivermectin, and it usually arrives the same way. Someone has heard about a man who was given three months to live, took a dog dewormer, and walked away cancer-free. It is a remarkable story, and it has been repeated millions of times.

I want to treat that story with respect rather than contempt, because the people repeating it are frightened and looking for hope, and because real laboratory science underlies it. But one detail in the original story almost never survives the retelling, and once you know it, the whole picture changes.

The story everyone has heard, and the part that gets left out

In 2016, Joe Tippens, an Oklahoma businessman, was diagnosed with small cell lung cancer that had spread widely. His prognosis was measured in months. On a veterinarian’s suggestion, he began taking canine fenbendazole along with vitamin E, curcumin, and CBD oil. His later scans showed no evidence of disease, and he published the protocol on a blog that has since been read by an enormous audience.

Here is what usually goes missing. At the same time, Mr. Tippens was enrolled in a clinical trial of pembrolizumab, an immune checkpoint inhibitor, at MD Anderson Cancer Center. Pembrolizumab is a genuinely powerful drug that produces durable remissions in a subset of lung cancer patients, which is precisely why it was in a trial and precisely why he was in it. This fact is not obscure. The peer-reviewed literature discussing his case notes it.

When two things happen at once, and one is a proven immunotherapy, no honest observer can assign credit to the other. That is not a technicality. It is the entire difference between an anecdote and evidence.

The story spread anyway. In South Korea, a September 2019 video recounting it reached millions of viewers and triggered a nationwide run on veterinary dewormer, with monthly sales rising severalfold and pharmacies selling out. Researchers at Korea’s National Cancer Center later published a formal study of how the misinformation moved from television to YouTube to patients.

What the laboratory research actually shows

Fenbendazole belongs to the benzimidazole family, which works by binding tubulin, the protein that forms the internal scaffolding cells use to divide. Because rapid division defines cancer, this mechanism is worth taking seriously. Some cancer drugs already in use, including the taxanes and vinca alkaloids, target the same machinery.

The most cited paper is by Dogra and colleagues, published in Scientific Reports in 2018. Working in human non-small cell lung cancer cells, they found that fenbendazole acts as a moderate microtubule destabilizer, stabilizes the p53 tumor suppressor, and inhibits glucose uptake by reducing GLUT transporters and hexokinase II, a key enzyme of glycolysis. It caused cancer cell death through several converging pathways. That is a legitimate finding, and it is why the idea has not simply been laughed off.

The animal data are where the story gets complicated, and they deserve careful reading rather than selective quoting.

The famous “mouse chow” study is Gao and colleagues, published in 2008. In mice with human lymphoma, fenbendazole alone did not slow tumor growth. Only fenbendazole combined with supplementary vitamins produced a significant effect. The paper warned laboratory researchers that fenbendazole in animal feed could confound their tumor experiments. It was never a demonstration that fenbendazole treats cancer.

More recently, Jung and colleagues tested fenbendazole in a mouse lymphoma model in 2023. In the dish, it arrested cell division and killed cells, exactly as expected. In the living animal, it had no anticancer effect: tumors grew the same as controls, and the mice lost weight rapidly. More troubling for anyone taking it alongside immunotherapy, the treated tumors showed higher PD-L1 expression and a higher proportion of immunosuppressive M2 macrophages, changes that point in the wrong direction for immune control of a tumor.

Other models have shown positive results, so the in vivo picture is mixed rather than uniformly negative. But “mixed in mice” is a very long way from where the internet has taken this.

The problem of getting enough of it into a person

Here is the pharmacology that rarely makes it into a protocol post. The concentrations that kill cancer cells in these experiments are around 1 micromolar, roughly 300 nanograms per milliliter. Fenbendazole is poorly soluble in water and poorly and erratically absorbed from the gut, which is a large part of why it works so well as a dewormer: it stays in the intestine, where the worms are.

Fenbendazole has never been given to humans in a formal pharmacokinetic study, so nobody can tell you what blood level a given dose produces. The only human exposure data come indirectly, from first-in-human studies of oxfendazole, a related compound that the body partially converts back into fenbendazole. In those studies, fenbendazole appeared only as a minor back-metabolite at a small fraction of the parent drug’s level.

Put those two facts side by side. The concentration needed to kill cancer cells in a dish is known and measurable. The concentration a person actually achieves after swallowing granules has never been measured, and the one indirect estimate available sits well below it. A poorly soluble, erratically absorbed compound, given by mouth, with no human dosing study behind it, is not a combination that inspires confidence that anything meaningful is reaching a tumor. Nobody circulating a milligram figure online can tell you otherwise, because no study has been done in a human being.

Why researchers study a different drug in the same family

If the benzimidazole mechanism is promising, why are there no fenbendazole cancer trials?

Because fenbendazole is a veterinary drug that has never been approved for human use anywhere, has never been through a human trial, and has no human dose, no human pharmacokinetic data, and no human safety database. Researchers who want to test this mechanism in people use mebendazole, its close relative, which is approved for human parasitic infections and therefore has decades of human safety and dosing data. Mebendazole has been tested in a phase 1 trial with temozolomide in newly diagnosed high-grade glioma, and in trials in gastrointestinal and colorectal cancer.

That glioma trial is worth pausing on for a different reason. At the highest dose tested, four patients developed grade 3 elevations in liver enzymes, which reversed when the dose was lowered or stopped. Even the human-approved cousin, given under close medical supervision, produced significant liver toxicity at high doses.

Which brings us to what is actually documented in humans who take fenbendazole.

The liver injuries are real, published, and severe

There are now at least four peer-reviewed case reports of liver injury in cancer patients taking fenbendazole. These are not rumors. They include laboratory values, formal causality scoring, and in one case a liver biopsy.

Yamaguchi and colleagues described an 80-year-old woman with advanced lung cancer, stable on pembrolizumab for nine months, who began taking fenbendazole based on social media information. She developed liver injury with an ALT around 487 U/L, which resolved within about six weeks of stopping the fenbendazole while she continued her immunotherapy. Her tumor did not shrink.

Thakurdesai and colleagues reported a 67-year-old woman with a history of colon cancer who took fenbendazole roughly three times weekly for about a year. She developed jaundice, with an AST of 1,869 U/L, an ALT of 2,600 U/L, a total bilirubin of 13.3 mg/dL, and an INR of 1.6. Her liver biopsy showed centrilobular necrosis. It took three months for her liver tests to normalize after stopping.

Krishnan and colleagues reported a 47-year-old woman with metastatic colon cancer receiving nivolumab and relatlimab. She had taken fenbendazole 222 mg three times weekly for about six weeks, then increased to 222 mg daily, and developed severe hepatocellular injury. Structured causality scoring identified fenbendazole as the probable cause. She improved rapidly after stopping and resumed immunotherapy without recurrence.

Powderly and colleagues described a 65-year-old man with prostate cancer who took veterinary fenbendazole and ivermectin together for about three months on the advice of an online cancer support group. His ALT reached 1,764 U/L and AST 1,132 U/L. A full workup for viral, autoimmune, biliary, and metabolic causes was negative, and formal scoring rated the anthelmintics as the highly probable cause. His enzymes fell 58% within nine days of stopping and normalized within six weeks.

The National Institutes of Health’s LiverTox database now lists fenbendazole as a probable cause of clinically apparent liver injury, noting that onset ranges from days to as long as a year, that the pattern is typically hepatocellular, and that while most cases are mild to moderate and reversible, some are severe and potentially life-threatening.

Every one of these patients recovered after stopping. That is genuinely reassuring, and it is also why the injury has to be found: someone has to be looking.

Why liver injury here is doubly serious

These cases carry a second harm unrelated to the liver itself.

Abnormal liver tests are common during cancer treatment, and the two most likely explanations a clinician will consider are the chemotherapy and, in a patient on immunotherapy, immune-related hepatitis. Immune-related hepatitis is treated with high-dose steroids and frequently means stopping the immunotherapy permanently.

In the Krishnan and Yamaguchi cases, the teams learned about the fenbendazole, correctly identified it as the cause, and kept both patients on treatments that were working. Had that information not surfaced, the obvious conclusion would have been the drug that was actually helping.

This is the quiet cost of undisclosed use. It does not simply add a risk. It corrupts the interpretation of every abnormal lab that follows.

What the rest of the benzimidazole family tells us

Because fenbendazole has no human safety data of its own, the most reasonable place to look is its approved relatives, taken at high doses for long periods.

The prescribing information for albendazole carries warnings for bone marrow suppression, including aplastic anemia, agranulocytosis, and pancytopenia, with reported fatalities. These occur predominantly with prolonged rather than short courses, which is exactly what a cancer protocol involves. The label also treats elevated liver enzymes as a recognized adverse effect and requires blood counts at the start of each treatment cycle and every two weeks during therapy, along with liver function monitoring. Patients with pre-existing liver disease are at substantially higher risk.

Benzimidazoles are also established animal teratogens, which matters for anyone of reproductive age.

None of this proves fenbendazole behaves the same way. But the mechanism is shared, the exposure in these protocols is far longer than any labeled use, and no human monitoring system exists to catch problems if they occur.

The rest of the protocol carries its own risks

The Tippens protocol is not fenbendazole alone, and the companions deserve scrutiny.

High-dose vitamin E has genuine anticoagulant activity and increases bleeding risk, which is a real concern in patients who are thrombocytopenic from chemotherapy or taking anticoagulation for a cancer-associated clot. The National Institutes of Health notes that oncologists generally advise against antioxidant supplements during chemotherapy or radiotherapy because they may reduce the effectiveness of those treatments, and that high doses may interact with alkylating agents and antitumor antibiotics. A meta-analysis linked doses of 400 IU or more daily to a small increase in all-cause mortality.

Curcumin and CBD both affect the same liver enzyme systems that metabolize many oral cancer drugs, adding another layer of unpredictability on top of a compound whose own human handling has never been measured. Within this drug family, corticosteroids are known to raise blood levels of the active metabolite, which matters given how commonly dexamethasone is used in oncology.

What you are actually swallowing

Fenbendazole is sold only as a veterinary product: granules, paste, and liquid suspensions formulated for dogs, cattle, and horses. These are made to animal health standards, not human pharmaceutical ones. There are no human purity specifications, no human labeling, and no guarantee of dose uniformity from packet to packet. Products bought from online resellers and repackagers marketed as “human grade” carry additional risks of counterfeiting and contamination. ASCO’s notice specifically warns that veterinary formulations may contain impurities or inconsistent concentrations.

The number in the protocol, 222 mg three days on and four days off, comes from the amount of fenbendazole in a packet of dog dewormer. It is not a dose derived from any human study, because no such study exists.

The two harms that dwarf the rest

First, nondisclosure. In a survey of 86 South Korean cancer patients who had used non-prescription anthelmintics, 96.5% did not tell their clinicians. In a United States national survey of cancer patients and survivors using complementary or alternative medicine, 29.3% did not disclose it, most often because nobody asked. A treatment plan built on incomplete information can fail for reasons no one can trace.

Second, delay. Johnson and colleagues studied 281 patients with curable breast, prostate, lung, or colorectal cancer who chose alternative medicine instead of conventional treatment. Their risk of death was two and a half times higher, with five-year survival of 54.7% compared with 78.3%. A companion study found that patients using complementary medicine also had roughly double the risk of death, and that the excess risk was explained by their higher rate of refusing or delaying standard treatment. The danger was not the supplement. It was the time lost.

Clinical trial eligibility is another issue. Trials routinely exclude patients taking concurrent unapproved anticancer agents or with unexplained laboratory abnormalities, which means fenbendazole use can close a door that might matter later.

What monitoring can and cannot catch

Periodic liver enzymes will detect hepatocellular injury, and a complete blood count will detect falling blood counts. Those are the two harms most worth watching for, and they’re why anyone using this should have both checked regularly rather than never.

But the honest accounting has to include what no test can see. No assay verifies what is actually in a packet of veterinary granules. Hypersensitivity reactions can appear without laboratory warning. No panel measures whether a supplement stack is altering the blood level of an oral targeted therapy. No test captures a small reduction in how well immunotherapy is working, and if that treatment underperforms, the failure will be attributed to the cancer. Liver monitoring samples rather than watches, and one of the published cases went from a tolerated schedule to severe injury after a dose increase.

Monitoring lowers some of these risks. It eliminates none of them, and it cannot see most of them.

Where things actually stand

In May 2026, the American Society of Clinical Oncology issued a clinical notice stating that ivermectin and fenbendazole should not be used to treat cancer, or as an adjunct to established cancer therapy, outside the safeguards of a well-designed clinical trial, citing the absence of robust clinical evidence together with the potential for toxicity and harmful drug interactions. The American Cancer Society states that fenbendazole has never been tested in human studies and has never been approved for human use for any purpose.

It is also worth noting that the small case series most often cited as evidence that fenbendazole produced remissions was retracted by its journal in January 2026 over an undeclared conflict of interest, with the journal noting that the first author offered services related to the study’s topic. Whatever one makes of the underlying cases, that paper can no longer be cited as validated literature.

A closing thought

The appeal of this story is not irrational. It contains a real mechanism, a real laboratory finding, and a man who survived a cancer he was not supposed to survive. What it does not contain is the thing that would make it a treatment: evidence that the drug, and not the immunotherapy he was receiving at the same time, is what saved him.

We are stewards of bodies with real protective systems already in place, and the liver is doing the quiet work in this particular story. It is also the organ that has repeatedly shown up damaged in the published record of people who tried this.

If you are taking fenbendazole, or considering it, tell your oncology team. Disclosure does not make the practice safe, and nothing here should be read as endorsing it. It simply keeps the people responsible for your care from mistaking one problem for another, at a moment when that mistake could cost you a treatment that is working.

References

Fenbendazole and Cancer: The Story, the Science, and the Issues Patients Need to Hear

Dr. Daniel Thomas, DO, MS